MedTrace Logo

Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (13.3mg/24h)

NCT05853341 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2023-10-19

No results posted yet for this study

Summary

The present clinical trial will be conducted in order to compare the bioavailability of rivastigmine and to assess bioequivalence at steady-state of the Test product RID-TDS 13.3 mg/24 h (Luye Pharma AG, Germany) and the marketed Reference product Exelon® 13.3 mg/24 h transdermales Pflaster (Novartis Pharma GmbH, Germany) after multiple patch applications. Each of both treatments will last for 11 days with a washout period of 14 days between the treatments.

Conditions

  • Healthy

Interventions

DRUG

RID-TDS 13.3 mg/24 h

3 consecutive applications of 1 patch (1st patch for 4 days, 2nd patch for 3 days, 3rd patch for 4 days) covering an 11-day period

DRUG

Exelon® 13.3 mg/24 h

11 consecutive applications of 1 patch (each patch will be applied for 1 day) covering an 11-day period

Sponsors & Collaborators

  • SocraTec R&D GmbH

    collaborator OTHER

  • SocraMetrics GmbH

    collaborator INDUSTRY

  • Luye Pharma Group Ltd.

    lead INDUSTRY

Principal Investigators

  • Juliane Koerner, MD · SocraTec R&D GmbH

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-05-02
Primary Completion
2023-07-02
Completion
2023-07-17

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05853341 on ClinicalTrials.gov